Skip to main content
Gujarat Themis Biosyn Ltd. logo

Gujarat Themis Biosyn Ltd. — Investor Relations & Filings

Ticker · GUJTHEM ISIN · INE942C01045 LEI · 3358009IT99XRO254Q79 BSE.NS Manufacturing
Open in API
Filings indexed 697 across all filing types
Latest filing 2025-12-30 Regulatory Filings
Country IN India
Listing BSE.NS GUJTHEM

About Gujarat Themis Biosyn Ltd.

https://www.gtbl.in

Gujarat Themis Biosyn Ltd. specializes in the manufacture of active pharmaceutical ingredients and intermediates through advanced fermentation technology. The company focuses on the production of fermentation-based bulk drugs, with a primary product portfolio that includes Rifampicin intermediates and Lovastatin. Utilizing large-scale fermentation processes, the organization engages in strain improvement and media optimization to enhance yield and efficiency. The company operates a dedicated manufacturing facility equipped for complex biotechnological processes. Through technical collaborations with international entities, it has integrated specialized expertise in fermentation science to support the development of high-purity chemical compounds. Its operations are centered on providing essential building blocks for various therapeutic applications, maintaining a focus on technical precision and process-driven manufacturing excellence.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges reporting on the special window for re-lodgement of transfer requests of physical shares, referencing a SEBI circular. It states that no cases were received for the months of October and November 2025. The document is short (1927 characters) and serves as a compliance update or regulatory communication rather than a financial report or detailed filing. It does not contain financial statements, audit information, or management discussion. It is an official regulatory update related to share transfer procedures, fitting best under Regulatory Filings (RNS).
2025-12-30 English
Please refer to the attachment.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding a newspaper publication notice about a special window for re-lodgement of transfer requests of physical shares. It references a SEBI circular and includes newspaper clippings and other unrelated news articles. The content is primarily an announcement of a notice publication and related regulatory compliance, not a financial report or detailed filing. The document length is about 15,000 characters but the content is an announcement and not a full report. There is no financial data, no management discussion, no audit information, no earnings release, or other detailed report content. Therefore, it fits best as a Regulatory Filing (RNS) as a general regulatory announcement and compliance document.
2025-12-30 English
Please refer to the attachment.
Regulatory Filings
2025-12-30 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notification about the closure of the trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. It informs the stock exchanges about the trading window closure period related to the upcoming financial results announcement for the quarter ending 31st December 2025. The document does not contain any financial data, results, or detailed report but is an announcement related to compliance and trading restrictions. The document length is short (1967 characters) and it is an intimation letter rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-12-26 English
Please refer to the attachment.
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about the closure of the trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. It informs about the trading window closure period around the upcoming quarterly financial results announcement but does not contain any financial data or results itself. The document is short (1967 characters) and serves as an announcement related to regulatory compliance and insider trading restrictions, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2025-12-26 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter from Gujarat Themis Biosyn Limited addressed to stock exchanges, referencing the publication of UnAudited Financial Results for the quarter and half year ended 30th September 2025. It includes a copy of newspaper advertisements as required by SEBI Listing Regulations. The content primarily announces the publication of financial results in newspapers and attaches the newspaper articles. There is no detailed financial data or comprehensive financial statements within the text itself, only a notification of the results' publication. The document length is 15,000 characters, but the content is an announcement of the publication of financial results, not the results report itself. Therefore, according to the MENU VS MEAL rule, this is a Report Publication Announcement (RPA).
2025-11-11 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.